Caris Life Sciences, Inc.
About Caris Life Sciences, Inc.
Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $812.0M
- Net income
- -$68.1M
- Total assets
- $1.1B
- Market cap
- $4.7B
- Operating margin
- 5.6%
- Net margin
- -8.4%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $812.0M
- Operating expenses
- $766.9M
- Operating income
- $45.1M
- Income tax
- $0
- Net income
- -$68.1M
- EPS (basic)
- $-3.22
- EPS (diluted)
- $-3.22
Balance sheet
- Total assets
- $1.1B
- Current assets
- $997.8M
- Total liabilities
- $548.4M
- Current liabilities
- $127.1M
- Shareholders’ equity
- $577.3M
Cash flow
- Operating cash flow
- $83.2M
- Investing cash flow
- -$16.3M
- Financing cash flow
- $665.0M
- Net cash flow
- $731.9M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $4.7B
- EPS (diluted)
- $-3.22
- Dividend yield
- 7.43%
- Shares outstanding
- 288.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 18, 2025
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $68.1M in FY2025.
- Revenue grew 133% from FY2017 to FY2025.
- Trading 59% below its 52-week high.
- Pays a dividend yielding about 7.43% annually.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Caris Life Sciences, Inc..
Write a review
News about Caris Life Sciences, Inc.
News & sentiment via Polygon.io
